Price
324.65
-0.25%52W Range
Market Cap
₹1,092.94 Cr
Traded: ₹2.86 Cr (0.26%) 0.0x
Free Float: ₹382.31 Cr (0.75% of FF traded)
Volume · 60D trend
87.92 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +11.0% | -1.0% | -2.0% | -- | +14.0% | Stable |
| ROE | +12.0% | +8.0% | +3.0% | -- | -- | Decelerating |
| Return | +18.0% | -5.0% | -9.0% | -27.0% | -- | Decelerating |
| Profit | +17.0% | -13.0% | -1.0% | -- | +14.0% | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2026PDF ↗ | Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 176 | 166 | 153 | 161 | 148 | 149 | 154 | 123 | 133 | 132 | 134 | 109 | 101 | 130 | 154 |
| Expenses | 145 | 137 | 130 | 131 | 121 | 124 | 143 | 101 | 109 | 108 | 118 | 89 | 82 | 108 | 132 |
| Operating Profit | 31 | 29 | 23 | 31 | 27 | 25 | 12 | 22 | 25 | 24 | 16 | 20 | 19 | 22 | 22 |
| Other Income | 1 | 1 | -34 | 1 | 0 | 1 | 13 | -1 | 4 | 0 | -36 | -7 | -7 | -55 | -7 |
| Interest | 6 | 6 | 6 | 6 | 6 | 5 | 6 | 6 | 8 | 8 | 6 | 7 | 8 | 9 | 6 |
| Depreciation | 8 | 7 | 8 | 7 | 7 | 6 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 5 |
| Profit Before Tax | 18 | 16 | -24 | 19 | 15 | 14 | 11 | 8 | 14 | 9 | -33 | -1 | -3 | -48 | 5 |
| Tax % | 23.0% | 16.0% | -6.0% | 17.0% | 24.0% | 17.0% | 1.0% | -39.0% | 30.0% | 23.0% | -10.0% | 58.0% | 4.0% | 0.0% | 21.0% |
| Net Profit | 14 | 14 | -23 | 16 | 11 | 12 | 11 | 12 | 9 | 7 | -30 | -2 | -3 | -48 | 4 |
| Exceptional Items | -0 | -0 | -37 | -0 | -1 | -0 | -0 | -3 | 1 | -1 | -42 | -8 | -9 | -55 | -8 |
| EPS (Rs) | 4.2 | 4.1 | -6.8 | 5.0 | 3.5 | 3.8 | 3.5 | 3.7 | 3.0 | 2.6 | -10.8 | -0.8 | -1.3 | -17.5 | 1.3 |
| Sales Growth (YoY) | 18.9% | 11.4% | -0.7% | 30.9% | 11.3% | 12.9% | 14.9% | 12.8% | 31.7% | 1.5% | -13.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 6.0% | 8.5% | -5.0% | 8.8% | -0.7% | -3.3% | 25.2% | -7.5% | 0.8% | -1.5% | 22.9% | 7.9% | -22.3% | -15.6% | -- |
| OP Growth (YoY) | 14.8% | 16.0% | 91.7% | 40.9% | 8.0% | 4.2% | -25.0% | 10.0% | 31.6% | 9.1% | -27.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 6.9% | 26.1% | -25.8% | 14.8% | 8.0% | 108.3% | -45.5% | -12.0% | 4.2% | 50.0% | -20.0% | 5.3% | -13.6% | 0.0% | -- |
| Profit Growth (YoY) | 15.5% | 14.1% | 19.2% | 7.6% | 49.3% | 51.8% | -5.9% | 171.0% | 62.9% | 14.1% | 10.6% | -67.0% | -75.9% | -51.0% | -- |
| EPS Growth (YoY) | 19.0% | 8.5% | -291.8% | 33.7% | 17.3% | 45.4% | 132.7% | 563.8% | 340.0% | 114.8% | -933.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 3.0% | 159.9% | -236.9% | 40.9% | -6.1% | 5.9% | -4.6% | 23.7% | 16.3% | 123.8% | -1255.0% | 36.0% | 92.8% | -1443.8% | -- |
| OP Margin | 17.6% | 17.5% | 15.0% | 19.3% | 18.2% | 16.8% | 7.8% | 17.9% | 18.8% | 18.2% | 11.9% | 18.4% | 18.8% | 16.9% | 14.3% |
| Net Margin | 8.0% | 8.4% | -15.0% | 9.9% | 7.4% | 8.1% | 7.1% | 9.8% | 6.8% | 5.3% | -22.4% | -1.8% | -3.0% | -36.9% | 2.6% |
| Material Cost % | 52.0% | 52.0% | 53.0% | 50.0% | 50.0% | 54.0% | 61.0% | 50.0% | 50.0% | 50.0% | 63.0% | 47.0% | 44.0% | 58.0% | 59.0% |
| Employee Cost % | 11.0% | 11.0% | 11.0% | 10.0% | 11.0% | 10.0% | 10.0% | 12.0% | 11.0% | 10.0% | 8.0% | 11.0% | 11.0% | 8.0% | 7.0% |
| P/S | 1.67 | 1.83 | 2.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 50.49 | 59.22 | 71.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.96 | 2.15 | 2.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation for Audio Recording of Earnings Call for Q2FY27
Intimation for newspaper publication
Statement of Deviation & Variation for the quarter ended September 30, 2026
Monitoring Agency Report for the quarter ended September 30, 2026
Financial Results for the quarter ended September 30, 2026
Outcome of the Board Meeting held on 17th October 2026
Press Release on the financial results of the Company for the quarter ended September 30, 2026
Receipt of Hon''ble NCLT Order approving acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis
Earning Call Invite
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 for the sale of a business unit of the Company
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2026 ,inter alia, to consider and approve the un-audited financial results ....
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Intimation for closure of Trading Window
Submission of Voting Results and Scrutinizer''s Report
Proceedings of the 33rd Annual General Meeting of the Company held on September 21, 2026
Intimation of Record Date for the payment of Final Dividend for the financial year 2025-26
Intimation for newspaper publication- Dispatch of Notice of 33rd Annual General Meeting and Annual Report for the financial year 2025-26
Intimation of the Annual Report for the financial year 2025-26
Intimation for Business Responsibility and Sustainability Report for the financial year 2025-26
Intimation of 33rd Annual General Meeting and dispatch of Annual Report of the Company for the financial year 2025-26
Intimation for Inland Letters sent to Shareholders
Intimation for Newspaper Publication with respect to 33rd Annual General Meeting of the Company
Intimation of allotment of equity shares pursuant to exercise of ESOPs
The Company has received the approval from DCGI to manufacture and market Cenobamate API and Tablets
Revision in Credit Rating
Transcript of Earnings Call for Q1FY27
Intimation for Newspaper Publication
Intimation for Audio Recording of Earnings Call for Q1FY27
Financial Results for the quarter ended June 30, 2026
Outcome of the Board Meeting held on July 20, 2026
Earnings Call Invite
Earnings Call Invite
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
Compliance Certificate under Regulation 74(5) of SEBI (DP), Regulations, 2018 for the quarter ended June 30, 2026
The Company has received a recommendation from SEC-CDSCO to manufacture and market Cenobamate Tablets
Intimation for closure of Trading Window
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 for the sale of a business unit of the Company
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anil Jain
Annual Secretarial Compliance Report
Intimation for Newspaper Publication
Press Release for the quarter and year ended 31st March 2026
Statement of Deviation & Variation for the quarter ended 31st March 2026
Monitoring Agency Report for the quarter ended 31st March 2026
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 for the Appointment of Auditors
Outcome of the Board Meeting
Financial Results for the quarter and financial year ended 31st March 2026
Intimation of approval received for listing of 20,79,409 equity shares of ?5/- each allotted pursuant to conversion of warrants issued on preferential basis
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026 ,inter alia, to consider and approve 1. Audited Financial Results ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Annual Reports
15Credit Ratings
6Held by ETFs
1 ETFs hold BAJAJHCARE · sorted by weight
Held by Mutual Funds
2 schemes hold BAJAJHCARE · sorted by weight